"During the Quarter, the Company successfully commenced a small-scale commercial trial for a new Joint Health Supplement produced using MicroMAX® technology, under a new direct to consumer brand on the Amazon platform in the U.S. MicroMAX® is a patented encapsulation technology platform designed to encapsulate microscopic droplets of oil in a special food grade material, to protect bioactive ingredients from oxidation, and help deliver them to the gastrointestinal (GI) tract for better absorption. In January 2020, CannPal was granted the global exclusive rights to commercialise patented MicroMAX® microencapsulation technology by the commonwealth scientific and Industrial research organisation (CSIRO) for use in the field of Animal Therapeutics [ASX Announcement: Jan 6, 2020]."
AC8 Price at posting:
14.0¢ Sentiment: None Disclosure: Not Held
